"Bahrain Pharmaceuticals & Healthcare Report Q3 2016" now available at Fast Market Research

Bahrain's p harmaceutical market will experience slight growth in 2016 as a result of medicine price cuts implemented in late 2015. The country ' s rising prevalence of lifestyle-related diseases and the uptake of compulsory health insurance will provide strong opportunities for multinational pharmaceutical companies in the coming years. Innovative drug companies will show increasing interest in the region for sales of high-value products for the treatment of chronic diseases such as diabetes. However, rising healthcare costs and lower oil prices impacting government revenues will lead to cost-containment measures focussed on the healthcare and pharmaceutical sectors.

Full Report Details at
- http://www.fastmr.com/prod/1170489_bahrain_pharmaceuticals.aspx?afid=301

Headline Expenditure Projections

Pharmaceuticals: BHD131mn (USD347mn) in 2015 to BHD140mn (USD370mn) in 2016; +6.8% in both local currency and US dollar terms. Forecast in line with last quarter.
Healthcare: BHD631mn (USD1.67bn) in 2015 to BHD684mn (USD1.81bn) in 2016; +8.4% in both local currency and US dollar terms. Forecast in line with last quarter.

Risk/Reward Index

In our Q216 matrix for the Middle East and Africa (MEA), Bahrain score remains at 52.0 out of 100 and is ranked seventh out of the 31 markets surveyed in the region, just below Qatar (52.4). The country's position is propped up by its favourable risks profile, as its longer-term rewards potential remains weighed down by its small population. On the other hand, Bahrain's well-developed business environment and demographic and epidemiological trends will continue to provide commercial opportunities for innovative drugmakers.

Latest Updates

In February 2016, Bahrain health officials travelled to the Baltic State of Estonia looking to learn about health insurance reforms in other countries as a possible template for its own ambitious healthcare reforms.

In January 2016, The Royal Bahrain Hospital has signed three agreements of cooperation with Russian healthcare companies, which will establish a cancer treatment department and provide the hospital with the latest equipment and Russian technologies.

In January 2016, Bahrain approved a new pharmaceutical manufacturing plant by Bahrain Pharma, with three other plants expected for approval under a joint collaboration between Bahraini investors and investors from the Gulf Cooperation Council, India and Kazakhstan.

BMI Economic View

Inflationary pressures will intensify following ongoing cuts to subsidies for food, diesel and utilities, although they will be mitigated by interest rates hikes in the second half of 2016, as the Central Bank will be forced to keep up with hikes from the US Federal Reserve.

BMI Political View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Italy Pharmaceuticals & Healthcare Report Q3 2016
- Belgium Pharmaceuticals & Healthcare Report Q3 2016